|Bid||0.345 x 0|
|Ask||0.360 x 0|
|Day's Range||0.340 - 0.350|
|52 Week Range||0.140 - 0.600|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.26|
Global Immuron Ltd sales revenue reached an AU$2million milestone continuing its upward trend and enjoying a 29% sales increase compared to FY17. US Travelan® sales continue to exceed expectations growing to AU$765k which represents a 114% increase over FY17. MELBOURNE, Australia, July 25, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases, is today pleased to announce the sales results of Travelan®, its commercially available, over-the-counter gastrointestinal and digestive health supplement, for the fiscal year ended June 30th, 2018.
Immuron Limited (ASX:IMC) (IMRN) is an Australian microbiome biopharmaceutical Company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. The Company is pleased to announce that the European Patent Office (EPO) has decided to Grant a patent for the use of a composition for the treatment of Non-alcoholic steatohepatitis (NASH). This patent (EPO Grant No. 2424890) is entitled “Anti-LPS enriched immunoglobulin preparations for the treatment and/or prophylaxis of a pathologic disorder”).
Three US Defense Health funded research projects on Travelan ® successfully completed Studies commissioned by the US Department of Defense to evaluate Travelan ®’ s ability to neutralise pathogenic bacteria ...
MELBOURNE, Australia, June 25, 2018-- Australian biopharmaceutical company Immuron Limited, is pleased to announce the appointment of New York based Mr. Richard Jay Berman to serve as a Director of the ...
U.S. exchanges are set to record their busiest year for IPOs from Asian firms since 2010 and may sustain the pace in 2018, as startups from Taiwan, Singapore, Indonesia and Vietnam join a flurry of Chinese firms that have already listed in the country. Chinese issuers have dominated U.S. IPO activity for several years, but Nasdaq and rival New York Stock Exchange (NYSE) have been increasingly targeting firms from fast-growing Southeast Asian economies and startups from Japan and Australia to counter their dependence on mainland companies.